Emerald Mutual Fund Advisers Trust Sells 52,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Emerald Mutual Fund Advisers Trust reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 17.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 242,802 shares of the biopharmaceutical company’s stock after selling 52,515 shares during the period. Emerald Mutual Fund Advisers Trust owned approximately 0.25% of Ultragenyx Pharmaceutical worth $7,303,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after acquiring an additional 29,984 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 669 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $353,000. Public Employees Retirement System of Ohio raised its position in shares of Ultragenyx Pharmaceutical by 2.0% in the second quarter. Public Employees Retirement System of Ohio now owns 27,885 shares of the biopharmaceutical company’s stock worth $1,014,000 after buying an additional 543 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Ultragenyx Pharmaceutical by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,652 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 557 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 2.9%

Shares of Ultragenyx Pharmaceutical stock opened at $23.40 on Friday. The firm has a market capitalization of $2.26 billion, a PE ratio of -3.94 and a beta of 0.15. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.41 and a 12 month high of $46.50. The business’s 50-day moving average price is $30.02 and its 200-day moving average price is $30.41.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. During the same quarter in the previous year, the firm earned ($1.40) EPS. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 3,081 shares of the company’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total value of $112,086.78. Following the completion of the sale, the chief financial officer owned 95,146 shares of the company’s stock, valued at approximately $3,461,411.48. This represents a 3.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

RARE has been the topic of a number of research analyst reports. Truist Financial decreased their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Jefferies Financial Group cut their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. Guggenheim decreased their price objective on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Leerink Partners lowered their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Finally, TD Cowen dropped their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $72.29.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.